Background
Point-of-care
tests for chlamydia (CT) and gonorrhoea (NG) could increase the uptake and
timeliness of testing and treatment, contribute to improved disease control and
reduce reproductive morbidity. The GeneXpert (Xpert CT/NG assay), suited to use
at the point-of-care, is being used in the TTANGO randomised controlled trial
(RCT) in 12 remote Australian health services with a high burden of sexually
transmissible infections (STIs). This represents the first ever routine use of
a molecular point-of-care diagnostic for STIs in primary care. The purpose of
this study was to explore the acceptability of the GeneXpert to primary care
staff in remote Australia.
Methods
In-depth
qualitative interviews were conducted with 16 staff (registered or enrolled
nurses and Aboriginal Health Workers/Practitioners) trained and experienced
with GeneXpert testing. Interviews were digitally-recorded and transcribed
verbatim prior to content analysis.
Results
Most
participants displayed positive attitudes, indicating the test was both easy to
use and useful in their clinical context. Participants indicated that
point-of-care testing had improved management of STIs, resulting in more timely
and targeted treatment, earlier commencement of partner notification, and
reduced follow up efforts associated with client recall. Staff expressed
confidence in point-of-care test results and treating patients on this basis,
and reported greater job satisfaction. While point-of-care testing did not
negatively impact on client flow, several found the manual documentation
processes time consuming, suggesting that improved electronic connectivity and
test result transfer between the GeneXpert and patient management systems could
overcome this. Managing positive test results in a shorter time frame was
challenging for some but most found it satisfying to complete episodes of care
more quickly.
Conclusions
In the context of a RCT, health professionals working in
remote primary care in Australia found the GeneXpert highly acceptable. These
findings have implications for use in other primary care settings around the
world.
Below: Influences on acceptability of Xpert CT/NG to operators in remote health services
Full article at: http://goo.gl/FUoJLa
By:
Lisa Natoli, Rebecca J. Guy, Louise Causer, Steven G.
Badman, John Kaldor, Lisa Maher
The Kirby Institute, UNSW
Australia, Sydney, NSW, Australia
Lisa Natoli, David Anderson
The Burnet Institute, Melbourne,
VIC, Australia
Mark Shephard
Flinders University
International Centre for Point of-Care Testing, Flinders University, Adelaide,
SA, Australia
Belinda Hengel
Apunipima Cape York Health
Council, Cairns, QLD, Australia
Annie Tangey
Ngaanyatjarra Health Service,
Alice Springs, NT, Australia
James Ward
South Australian Health and
Medical Research Institute, Adelaide, SA, Australia
Tony Coburn
Queensland Aboriginal and
Islander Health Council, Brisbane, QLD, Australia
More at: https://twitter.com/hiv
insight
No comments:
Post a Comment